Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI response largely aligns with the FDA label for indications and common adverse events, as well as mechanism-related statements. It correctly identifies multiple labeled indications (GERD, EE healing, maintenance, Zollinger-Ellison, etc.) and commonly reported adverse reactions. However, there are misclassifications (notably claims about duodenal ulcers and generics) and a partially supported claim regarding irreversible proton pump inhibition. Several non-label items (brand names, generic availability, patent landscape) are not supported by the label. Overall, the response is generally aligned but contains material misclassifications and some non-labeled assertions.
Category Scores
Accurate Statements
Esomeprazole sodium is a medication used to treat conditions associated with excess stomach acid.
Indications and Usage; 1.1 Healing of EE; 1.3 Treatment of Symptomatic GERD; 1.6 Zollinger-Ellison Syndrome
Esomeprazole sodium is used to treat gastroesophageal reflux disease (GERD).
Indications and Usage; 1.3 Treatment of Symptomatic GERD
Esomeprazole sodium is used to treat Zollinger-Ellison syndrome.
Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome; 1.6
Esomeprazole sodium is the S-isomer of omeprazole.
12.1 Mechanism of Action
Esomeprazole sodium is a proton pump inhibitor (PPI).
12.1 Mechanism of Action; general label discussion of PPIs
Esomeprazole sodium irreversibly blocks the H+/K+-ATPase enzyme system (the proton pump) in gastric parietal cells.
12.1 Mechanism of Action
This action decreases gastric acid secretion.
12.1 Mechanism of Action
Common side effects include headache.
6.1 Adverse Reactions
Common side effects include diarrhea.
6.1 Adverse Reactions
Common side effects include nausea.
6.1 Adverse Reactions
Common side effects include stomach pain.
6.1 Adverse Reactions
Common side effects include vomiting.
6.1 Adverse Reactions
Common side effects include gas.
6.1 Adverse Reactions
Long-term use of PPIs like esomeprazole sodium has been associated with an increased risk of fractures.
5.4 Bone Fracture
Long-term use of PPIs like esomeprazole sodium has been associated with an increased risk of vitamin B12 deficiency.
5.8 Cyanocobalamin (Vitamin B-12) Deficiency
Long-term use of PPIs like esomeprazole sodium has been associated with an increased risk of magnesium deficiency.
5.9 Hypomagnesemia and Mineral Metabolism
Unsupported Statements
The most well-known brand name for esomeprazole sodium is Nexium [3].
Brand names are not listed in the provided prescribing information.
Esomeprazole sodium is also available in generic forms [4].
Generic availability is not stated in the provided label sections.
Esomeprazole sodium is prescribed for treating duodenal ulcers [1].
Label 1.5 describes HP eradication to reduce duodenal ulcer recurrence; not a standalone 'treat duodenal ulcers' indication.
Esomeprazole sodium is prescribed for treating gastric ulcers [1].
Gastric ulcers are not listed as a labeled indication in the provided sections.
The patent landscape for esomeprazole sodium is complex, with various patents covering different aspects of the drug, including its formulation and method of use.
Patent landscape is not addressed in the provided label sections.
DrugPatentWatch.com tracks these patents and their expiration dates [8].
Patent-tracking sites are not addressed in the label.
For specific patent expiry information for esomeprazole sodium, one would need to consult detailed patent databases.
Not a labeled attribute.
Generic versions of esomeprazole sodium are available.
Generic availability is not stated in the provided label sections.
Generic versions typically offer a more cost-effective treatment option once brand-name patents expire [4].
Label does not provide generic pricing or market competition statements.
The availability of generics can lead to increased competition in the market.
Not addressed in the provided label.
Contradictions
Low
AI Statement
Esomeprazole sodium is the S-isomer of omeprazole.
Label Reference
12.1 Mechanism of Action
Important Omissions
Contraindications for esomeprazole magnesium for delayed-release oral suspension and for the combination products (amoxicillin/clarithromycin) are not discussed in the AI's set of claims; label contains listed contraindications in 4.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Major label-prescribed safety topics (common AEs, long-term fracture/B12/magnesium risks) are captured; no new safety concerns introduced by AI's evaluation.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Incorrectly judged some claims regarding duodenal ulcers (claim 13) and generic availability (claims 9, 33).
Suggested Improvement
Align all indication-related judgments to the exact label language (include HP eradication context for duodenal ulcers). Do not infer generic availability or pricing from label content. Clarify mechanism wording to reflect 'inhibition' rather than explicitly stating 'irreversibly' unless supported by the labeled mechanism text.